Cosmo and Glenmark announce the signing of Distribution and License Agreements for Winlevi® in Europe and South Africa
MUMBAI, India and DUBLIN, Sept. 27, 2023 /PRNewswire/ -- Cosmo Pharmaceuticals N.V. (SIX: COPN), (XETRA: C43) ("Cosmo") and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. ("Glenmark"), today announced the signing of distribution and license agreements for Winlevi® (clascoterone cream 1%) in Europe and South Africa.
- MUMBAI, India and DUBLIN, Sept. 27, 2023 /PRNewswire/ -- Cosmo Pharmaceuticals N.V. (SIX: COPN), (XETRA: C43) ("Cosmo") and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. ("Glenmark"), today announced the signing of distribution and license agreements for Winlevi® (clascoterone cream 1%) in Europe and South Africa.
- Alessandro Della Chà, CEO of Cosmo, said, "We are very pleased to partner with Glenmark.
- Their strong expertise in the commercialization of pharmaceutical compounds gives us great confidence in their ability to successfully market Winlevi®.
- Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements.